[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-transplant-failure-and-rejection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-transplant-failure-and-rejection":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100626379","plasma-and-radiologic-biomarkers-of-response-to-ecp-in-lung-transplant-recipients-with-clad-100626379",false,"NCT07434869","Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD","Inclusion Criteria:\n\n* Adults (≥18 years) or pediatric patients (7-17 years) who have had a single or double lung transplant\n* Diagnosed with CLAD (any stage) and prescribed ECP therapy\n* Ability to provide informed consent (or assent with parental consent for minors)\n\nExclusion Criteria:\n\n* Previously received ECP treatment\n* Receipt of anti-thymocyte globulin within 3 months or alemtuzumab within 12 months of ECP initiation\n* Contraindications to MRI (for MRI subgroup), including metal implants, claustrophobia, seizure disorder\n* Known allergy to gadolinium or impaired kidney function (eGFR \\\u003C30 ml\u002Fmin)\n* Pregnant or breastfeeding","ALL","7 Years",{"count":18,"type":19},25,"ESTIMATED","OBSERVATIONAL","This study is for people who have had a lung transplant and developed a condition called chronic lung allograft dysfunction (CLAD), which is a type of chronic rejection. Doctors often treat CLAD with a procedure called extracorporeal photopheresis (ECP), but it can take up to six months to know if the treatment is working. The goal of the study is to find early signs (biomarkers) that show whether ECP is helping, so patients can get the right care sooner.\n\nFor participants in the study, small blood samples will be collected at three points during ECP treatment and, for some participants, two MRI scans of the lungs will be performed-one before starting ECP and one after finishing treatment. The MRI uses a safe contrast dye to help us see changes in lung blood flow and tissue. Investigators will also look at certain immune cells in the blood.\n\nThis is not a study of a new drug or treatment-participants will receive the same ECP therapy their doctor already recommended. The study will help researchers understand how ECP works and identify markers that predict who benefits most. There is no direct benefit to participants, but participation may help improve care for future lung transplant patients.",[23,24,25],"Lung Transplant Failure and Rejection","CLAD, Bronchiolitis Obliterans","Extracorporeal Photopheresis",[27,28,29,30,31],"Chronic Lung Allograft Dysfunction (CLAD)","Chronic Lung Rejection","Bronchiolitis Obliterans Syndrome (BOS)","Lung Transplant Recipients","Restrictive Allograft Syndrome (RAS)","NOT_YET_RECRUITING","2026-02-25",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":19},"2026-03-01",{"date":40,"type":19},"2030-02-28",{"name":42,"class":43},"Brian Keller","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100568287","liquid-biopsies-for-lung-allograft-damage-classification---leonardo-100568287","NCT06679257","Liquid biopsiEs fOr luNg AllogRaft Damage classificatiOn - LEONARDO","Liquid Biopsies for Lung Allograft Damage Classification","LEONARDO","Inclusion Criteria:\n\n* Luing Transplanted and followed up within the reach of the study paricipating centres.\n\nA good understanding to read and write within the languages in which the consent is provided.\n\nExclusion Criteria:\n\n* Not Lung Transplanted or not followed up within the reach of the study paricipating centres.\n\nNo good understanding to read and write within the languages in which the consent is provided.","18 Years",{"count":54,"type":19},146,"LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this.\n\nThe current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance.\n\nThe research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status.\n\n.",[23,57],"Lung Transplant Infection","RECRUITING","2025-09-15",{"date":61,"type":36},"2025-09-16",{"date":63,"type":36},"2024-11-15",{"date":65,"type":19},"2030-12",{"name":67,"class":68},"Jesper Magnusson","OTHER_GOV",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":69},"100426771","diagnostic-and-prognostic-biomarkers-of-transplant-dysfunction-in-the-context-of-lung-transplantation-100426771","NCT04837339","Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation","DATACOL","Inclusion Criteria:\n\n* Men or women over 15 years of age\n* Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant\n* Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has\u002Fhave signed the informed consent.\n* Be affiliated with a Health Insurance plan.\n\nExclusion Criteria:\n\n* Pregnant, parturient and\u002For lactating woman\n* Hemoglobin level less than or equal to 8g\u002Fdl\n* Persons of full age who are subject to a legal protection measure or who are unable to express their consent\n* Persons under the protection of justice\n* Not being able to follow the study requirements for geographical, social or psychological reasons\n* Patient refusal.","15 Years",{"count":79,"type":19},900,"INTERVENTIONAL",[82],"NA","Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation.\n\nEach dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.",[85,86,87,23],"Lung Transplant Rejection","Lung Transplant Failure","Lung Transplant; Complications",[75],"2022-08-02",{"date":91,"type":36},"2022-08-03",{"date":93,"type":36},"2022-03-17",{"date":95,"type":19},"2037-03",{"name":97,"class":43},"Hopital Foch"]